Financials
- Fiscal year
- 2025
- Total assets
- €379,706
- Profit
- €56,641
- Solvency
- 66.4%
Total assets▼ 14.9%
Net result
20182025
C-THAT
ActiveSummary
C-THAT has been active since 2017 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €252,115 and a net result of €56,641. Equity is growing by ~24% per year across the filed fiscal years. Its solvency ranks better than 70% of 64 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.6% (low).
Overview
What they do
Manufacture of basic pharmaceutical products and pharmaceutical preparations
NACE 21100Business and other management consultancy NACE 70200Business consulting NACE 70220
1 site
How big
€379,706total assets 2025
- Staff
- 1.7 FTE
- Equity
- €252,115
- Profit
- €56,641
Turnover not published (abridged schema)
Who decides
- Holdings
- 1
Accounts 65 d early0 of 4 deeds read
Why 81- Higher-failure-rate sector+ Annual accounts: healthy financial profileLatest accounts filed on timeShow the evidence
Checked score
Score 2025
Axes · tick = 2024
Profitability87▼-4
Solvency91▼-9
Growth78=
Track record100
Bankruptcy probability, 12 months
0.6%
Low
0%0.5%1.5%4%10%≥ 25%
Credit up to €20,000 at 30 days acceptable
Liquidity ample (current ratio 2.75 against 3.82 in 2024; short-term debt: 33.6% and cash: 26.2% of total assets), and 33.6% of the assets are financed with debt.
Credit check for your own amount and term
Show the recommended maximum : and see how the verdict changes with amount, term and advance.
Signals
Three signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
66.4%
Return on assets
14.9%
Age of the figures
9 mo
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 21
Relative position
BE, all sectors
reference
Manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21)
about 14% more bankruptcies
← fewer bankruptcies
more bankruptcies →
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 27-05-2026, 65 days ahead of the deadline.
NBB · 8 filingsDeviation from the deadline
2025
65 d early
2024
2 d early
2023
20 d early
2022
31 d late
2021
31 d late
2020
1 d early
2019
6 d early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 7 accounts on average 5 days before the deadline; the sector median for financial year 2024 is 9 days before the deadline, and 32% of the sector filed late.
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. Usually files around 29 July (4 of the last 5 filed years within 33 days of that day).
Companies Code · seven monthsPosition in the running window
02-10-2026 today31-12-2026 close31-07-2027 deadline
- Annual accounts filedfiscal year 2025 · micro…
- Annual accounts filedfiscal year 2024 · micro…
- Annual accounts filedfiscal year 2023 · micro…
Key points
By topic
Network & group
- Holdings
- 1
1 holding
Timeline
- Events
- 12
- Since
- 2019
- Next accounts
- by 31-07-2027
- 27-05-2026Annual accounts filed
- 29-07-2025Annual accounts filed
- 11-07-2024Annual accounts filed
Support & recognitions
- Funding sources
- 1
- Flemish government
- €815awarded · 2022 - 2024
Company details
- Sites
- 1
- Legal form
- Private limited company
- Activity
- Manufacture of basic pharmaceutical products and pharmaceutical preparationsNACE 21100
- Founded
- 13-09-2017
- Year ends
- 31-12
- Peppol
- Reachable for e-invoices
Go further with this company
How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check What other support did companies like this one receive, and it did not?Subsidies How does this company compare with its sector?Sector benchmark
Your own company? See how customers, suppliers and banks see it and what to improve first.
Investigating this company? Keep it with today's facts in a case file.